Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Impedimed Limited (AU:IPD)
ASX:IPD
Holding AU:IPD?
Track your performance easily
Earnings Data
Report Date
―TBA Not Confirmed
Period Ending
―Consensus EPS Forecast
―Last Year’s EPS
―Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 21, 2019
|% Change Since: -7.41%
|Next Earnings Date:Aug 30, 2018
Earnings Call Sentiment|Neutral
The earnings call highlighted strong sales growth and increased contract pricing, indicating positive momentum and confidence in the business's future. However, challenges such as the cleanup of the legacy installed base and significant cash outflows were noted, which could impact short-term financial stability.Company Guidance
During the Q4 2024 earnings call for ImpediMed Limited, Parmjot Bains, the CEO, highlighted several key metrics and strategic initiatives. The company reported unaudited revenue of $2.9 million for the quarter, marking a 12% increase from the previous quarter's $2.6 million. ImpediMed sold 38 SOZO units, with 23 units sold in the U.S., demonstrating growing market acceptance. The company's lead pipeline grew by 168% for the quarter, contributing to a 380% increase since Q1 of the financial year 2024. Contract renewals in the U.S. saw an average price increase of 38%, reflecting the value customers place on the platform. The company's efforts to expand reimbursement coverage continue, maintaining 140 million covered lives, with a target of achieving 85% coverage. Financially, the company managed to reduce net operating cash outflows to $4.7 million, down from $6.3 million in the previous quarter, and expects to lower annualized operating cash expenditure by 10% in FY '25. The leadership team remains focused on accelerating progress toward cash flow breakeven, projected within a two-year timeframe.Increased SOZO Unit Sales
A total of 38 SOZO units were sold in Q4, with 23 sold in the U.S., reflecting growing acceptance and demand for the technology.
Significant Lead Pipeline Growth
The lead pipeline grew by 168% this quarter and by 380% since Q1 FY2024, indicating strong marketing strategies and effective sales lead generation activities.
Increased Contract Renewal Pricing
The average price of renewed contracts in the U.S. increased by 38%, demonstrating customer commitment and perceived value of the platform.
Economic Evaluation of Lymphedema Program
A New South Wales economic evaluation showed a 712% return on investment, translating to an estimated program NPV of $52 million, highlighting the clinical and economic benefits of the technology.
Revenue Growth
ImpediMed recorded unaudited revenue of $2.9 million for the quarter, a 12% increase compared with the previous quarter.
---
AU:IPD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AU:IPD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Aug 28, 2024 | AU$0.05 | AU$0.05 | -7.41% |
| Feb 26, 2024 | AU$0.09 | AU$0.08 | -6.98% |
| Aug 30, 2023 | AU$0.17 | AU$0.18 | +2.86% |
| Feb 23, 2023 | AU$0.06 | AU$0.06 | -3.45% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Impedimed Limited (AU:IPD) report earnings?
Currently, no data Available
What is Impedimed Limited (AU:IPD) earnings time?
Currently, no data Available
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Impedimed Limited stock?
The P/E ratio of Impedimed Limited is N/A.
What is AU:IPD EPS forecast?
Currently, no data Available
---